Biocartis has announced the launch of its first infectious disease test on the Idylla platform, as reported by PharmaBiz.

The Idylla Respiratory IFV-RSV Panel is designed for the qualitative detection of nucleic acids of influenza A, influenza A subtype H1, influenza A subtype H3, influenza A subtype 2009 H1, H275Y mutation of influenza A subtype 2009 H1, influenza B and RSV subtype A and RSV subtype B from nasopharyngeal swabs (NPS) of adult and pediatric patients, using the Idylla molecular diagnostics platform to aid in the diagnosis of respiratory viral infection.

Thanks to the fully integrated workflow and outstanding ease-of-use of the Idylla platform, the Idylla Respiratory IFV-RSV Panel can be performed in as little as 50 minutes and requires less than one minute of hands-on time.

After Biocartis launched its solid biopsy BRAF mutation test for melanoma and solid biopsy KRAS mutation test for colorectal cancer, this Idylla Respiratory IFV-RSV Panel is the first of a series of infectious disease tests that Biocartis and its partners are developing for use on the Idylla platform.

Rudi Pauwels, CEO Biocartis, states, “Collaboration is a key aspect of the strategy that we outlined at the time of our initial public offering, in order to accelerate our menu development and speed up our commercial reach. Janssen has been a long-standing and very supportive partner of Biocartis. We are therefore delighted with the launch of such a high performance quality Idylla Respiratory IFV-RSV Panel. The combination of oncology and infectious disease tests demonstrates the versatility of our Idylla platform, one of the reasons why Janssen Diagnostics chose to work with Biocartis.”

View the full story at www.pharmabiz.com